Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Hexarelin
Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) known for its potent ability to stimulate the release of growth hormone.
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context, not a protocol or recommendation.
Mass amounts available for comparison
- Lower range100 mcgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range500 mcgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Reported protocols for Hexarelin
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical, 1 preclinical and 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| Single-dose route and dose comparison in healthy volunteers12 healthy young adults | 1 or 2 mcg/kg intravenous; 1.5 or 3 mcg/kg subcutaneous; 20 mcg/kg intranasal; 20 or 40 mg oral | Single doses on separate test days | Intravenous, subcutaneous, intranasal and oral | Single administrationNot applicable | Journal of Clinical Endocrinology and Metabolism (PubMed)1994 |
| GH release rose with dose by every route, and 1 mcg/kg intravenously produced about twice the GH output of the same dose of GHRH. Relative bioavailability was 77% subcutaneous, 4.8% intranasal and 0.3% oral, which explains why the oral doses had to be tens of thousands of times larger than the injected ones. | |||||
| 16-week twice-daily course in older adults12 healthy elderly adults | 1.5 mcg/kg | Twice daily | Subcutaneous | 16 weeks, with a re-test 4 weeks after stopping4-week washout at the end restored the GH response | Journal of Clinical Endocrinology and Metabolism (PubMed)1998 |
| The GH response to a test injection fell from 19.1 to 12.3 mcg/L per hour by week 4 and to 10.5 by week 16, then recovered to 19.4 four weeks after stopping, so the attenuation was partial and reversible. Despite 16 weeks of dosing, IGF-1, IGF binding protein-3, body fat, lean mass and bone density did not change. | |||||
| Intranasal treatment of short children8 prepubertal short children aged 4 to 11.6 years | 60 mcg/kg | Three times daily | Intranasal | Up to 8 monthsNone described | Clinical Endocrinology (PubMed)1995 |
| Growth velocity rose from 5.3 to 8.3 cm per year and IGF-1 from 10.4 to 14.1 nmol/L, with no side effects reported. The study was small and uncontrolled, and a follow-up paper from the same group found the pituitary GH response was partly blunted within a week of starting. | |||||
| Acute cardiac effect during coronary bypass surgery24 men with coronary artery disease under general anesthesia | 2 mcg/kg | Single dose | Intravenous | Single administration, monitored for 90 minutesNot applicable | European Journal of Pharmacology (PubMed)2002 |
| Ejection fraction, cardiac index and cardiac output rose within 10 minutes and stayed up for about 90 minutes, while GHRH, recombinant GH and placebo did nothing, pointing to a GH-independent effect on the heart. This was a short intraoperative observation, not a treatment trial, and no study has tested repeated dosing for heart disease. | |||||
| Preclinical1 row | |||||
| Preclinical cardioprotection in hypophysectomized ratsHypophysectomized rats, hearts tested ex vivo after ischemia and reperfusion | 80 mcg/kg | Once daily | Subcutaneous | 7 daysNot applicable | Endocrinology (PubMed)1999 |
| Seven days of dosing prevented the worsening of ischemia-reperfusion injury caused by removing the pituitary, matching the effect of 400 mcg/kg GH, while a GH secretagogue that does not bind heart tissue did nothing. Because the rats had no pituitary, the protection could not have come from GH release. | |||||
| Community-reported3 rows | |||||
| Research dosing table with cycling for desensitization | 100-200 mcg (about 2 mcg/kg) | 1-3 times daily, fasted | Subcutaneous | 4 weeks on (some protocols 6 weeks)2 weeks off after 4 weeks on, or 4 weeks off after 6 weeks on | Community resource2026 |
| This 2026 guide anchors its 100-200 mcg range to the 2 mcg/kg figure from the human pharmacology studies and lists morning, pre-workout and bedtime slots at least two hours from food. It states that higher doses mainly add cortisol and prolactin rather than GH, and that the GH response falls to roughly half within 5-8 weeks of continuous use. | |||||
| Conservative, standard and stacked protocols | 100 mcg once daily (conservative); 200 mcg twice daily (standard); 100 mcg plus 100 mcg CJC-1295 without DAC (stacked) | Once or twice daily, morning and before bed | Subcutaneous, 5 mg vial in 2 mL giving 25 mcg per unit | 4-6 weeks onAt least 4 weeks off | Community resource2026 |
| A 2026 educational guide ties its 4-6 week ceiling directly to the 1998 desensitization study, arguing that most of the drop in GH response happens in the first four weeks and that a 4-week washout is what restored it in that trial. It describes IGF-1 rising 30-80% over a cycle as the expected lab change and calls year-round use the worst-value way to run the compound. | |||||
| Wiki dosing summary | 100-200 mcg per injection; 1-2 mcg/kg quoted for single-dose trial testing | 2-3 times daily on an empty stomach | Subcutaneous (abdomen or thigh), reconstituted in 1-2 mL bacteriostatic water | 8-12 weeks4 weeks off between cycles | Community resource2026 |
| This wiki page, updated in January 2026, lists a longer 8-12 week cycle than most guides while admitting in the same table that desensitization appears within 1-2 weeks of continuous use. It notes that no controlled trial has compared continuous with intermittent dosing and that no dose-optimization study exists for chronic use. | |||||
How a course is commonly described
- Weeks 1-2Community-reported
Community guides describe the strongest GH response in the first two weeks, with 100-200 mcg injected fasted once or twice a day and sleep and recovery changes reported early. The 1998 trial measured the first fall in GH output at week 1.
- Weeks 3-4Community-reported
Guides place the start of noticeable desensitization here and treat week 4 as the decision point for ending a cycle. In the human study the GH response had dropped to about 64% of baseline by week 4.
- Weeks 5-8Community-reported
Some protocols run on to 6-8 weeks, and one wiki lists 8-12 weeks, but the same sources describe the GH response as substantially blunted by this point and warn against raising the dose to compensate.
- BreakClinical
A 4-week off period is the most common recommendation, taken from the 16-week trial in which the GH response was back to baseline four weeks after the last injection. Shorter 2-week breaks appear in some charts.
- Clinical comparisonClinical
The only multi-week adult course on record is 1.5 mcg/kg twice daily for 16 weeks with no break, which changed neither IGF-1 nor body composition. Children received 60 mcg/kg intranasally three times a day for up to 8 months, and the cardiac studies used single 2 mcg/kg intravenous doses.
- The on-off cycling described by community sources is an inference from a single 16-week study in 12 older adults. No trial has compared cycled with continuous dosing or shown that cycling improves any outcome.
- In that 16-week study the GH response fell by about half yet IGF-1, fat mass and lean mass did not move, so the body-composition claims attached to community protocols have no human support.
- Hexarelin raises cortisol and prolactin as well as GH, is on the WADA prohibited list and has no approval anywhere. The rows above record what sources report, not endorsements of use.
Sources for this section (8)
- Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man
- Growth hormone status during long-term hexarelin therapy
- Intranasal administration of the GHRP hexarelin accelerates growth in short children
- Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery
- Growth hormone-independent cardioprotective effects of hexarelin in the rat
Plus 3 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Overview
Hexarelin (examorelin) is a synthetic six-amino-acid growth hormone-releasing peptide built from GHRP-6 by methylating the D-tryptophan at position 2, which makes it more resistant to breakdown. It acts on the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus and also binds the scavenger receptor CD36 in heart tissue, which is why it was studied both as a GH stimulus and for direct cardiac effects. European groups ran human pharmacology studies in the 1990s, including a 16-week course in older adults and intranasal treatment of short children, but development stopped and it was never approved anywhere; it is prohibited by WADA and sold only as a research chemical.
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 1
Research
Scientific studies on Hexarelin and its therapeutic applications
What is known and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Not graded
Research
Scientific studies on Hexarelin and its therapeutic applications
Amounts recorded for Hexarelin
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 1Dose · lower endpointSign in for schedule, duration and source context.100 mcg
- 2Dose · upper endpointSign in for schedule, duration and source context.500 mcg
Chemistry identifiers
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Sequence
His-D-(2-Me)Trp-Ala-Trp-D-Phe-Lys-NH2
Also listed as
Examorelin (INN, PubChem record title), EP-23905, MF-6003, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, UNII 09QF37C617, CHEMBL108335, CAS 208251-52-9 (second registry number listed by PubChem)
InChIKey
RVWNMGKSNGWLOL-GIIHNPQRSA-N
IUPAC name
(2S)-6-amino-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
Limitations and unknowns
Sources
1 link carried over from the earlier page, awaiting verification.